TCGA-BA-6873-01A-11R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.480
- MYC_TARGETS_V2+0.470
- INTERFERON_ALPHA_RESPONSE+0.460
- MYC_TARGETS_V1+0.410
- MITOTIC_SPINDLE+0.350
- WNT_BETA_CATENIN_SIGNALING+0.330
- INTERFERON_GAMMA_RESPONSE+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- OXIDATIVE_PHOSPHORYLATION-0.340
- ADIPOGENESIS-0.250
- BILE_ACID_METABOLISM-0.250
- NOTCH_SIGNALING-0.210
- XENOBIOTIC_METABOLISM-0.210
- PEROXISOME-0.180
- ESTROGEN_RESPONSE_EARLY-0.150
- CHOLESTEROL_HOMEOSTASIS-0.120
- P53_PATHWAY-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-A511-01A-21R-A262-07 | — | cohortSQ1 | 0.830 |
| 2 | TCGA-CN-5363-01A-01R-1436-07 | — | — | 0.810 |
| 3 | TCGA-85-7950-01A-11R-2187-07 | — | cohortSQ1 | 0.806 |
| 4 | ERR2208969 | — | — | 0.802 |
| 5 | GSM5359424 | — | — | 0.797 |
| 6 | 02fde1b1-c95c-4d8f-b57b-355b55072108 | — | — | 0.794 |
| 7 | SRR934755 | — | — | 0.793 |
| 8 | TCGA-BH-A0WA-01A-11R-A109-07 | — | E | 0.790 |
| 9 | TCGA-90-7767-01A-11R-2125-07 | — | cohortSQ1 | 0.768 |
| 10 | SRR5088924 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |